How long to take tucatinib/tucatinib

Tucatinib/Tucatinib is a prescription drug. It is approved to treat certain types of advanced breast cancer in adults. Specifically, Tucatinib is approved to treat HER2-positive (HER 2+) breast cancer that is either locally advanced (has spread to nearby tissue) and unresectable (cannot be removed with surgery), or metastatic (has spread to other parts of the body). Tukysa is approved for adults with cancer who have received one or more anti-HER2 treatments in the past.

Tucatinib works in a slightly different way than other drugs in this type of work. This drug increases treatment options for patients with HER2+ breast cancer when other drugs fail. Once a patient takes the first dose of the drug, tucatinib begins working on the cancer cells in their body. However, patients may not notice tucatinib working in their body. This is because this drug does not treat the symptoms of breast cancer. It helps stop cancer from getting worse. Doctors will order certain tests during a patient's treatment to check how well the medicine is working. If patients have any questions about the tests required during treatment, they should talk to their doctor.

Tucatinib contains the active drugtucatinib. This is a targeted therapy for HER2+ breast cancer. Targeted therapies work by blocking specific proteins that help cancer cells grow and reproduce (reproducing cells are making more cells). Tucatinib is a tablet that is taken orally twice daily and is available in two strengths: 50 mg and 150 mg.

In a clinical study, tucatinib was effective in treating advanced HER2+ breast cancer. After one year, people taking tucatinib were 46% less likely to have their cancer progress (get worse or spread further in the body) compared with people taking a placebo. After two years, people taking tucatinib were 34% less likely to die.